# OncoLens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncolens

- Industry: Healthcare IT
- Headquarters: Atlanta, US
- Website: www.oncolens.com
- Total disclosed funding: $25M
- Latest round: Series B (Oct 2, 2024)
- Investors on record: 6

## About

OncoLens is a U.S.-based company that specializes in providing a multidisciplinary cancer care platform aimed at improving patient outcomes through enhanced data management and clinical decision support.Founded in 2015 and headquartered in Atlanta, US, OncoLens focuses on revolutionizing cancer care with a unique platform. The company was established by Anju Mathew and Lijo Simpson. OncoLens has raised a total of USD 12.865 mn, with its most recent funding round being Series B, attracting investment from firms such as BIP Ventures and Cross-Border Impact Ventures on October 2, 2024. This funding supports its growth initiatives.OncoLens offers a comprehensive cancer care platform designed to enhance patient outcomes through efficient data management and clinical decision support. Their solutions cater to integrated delivery networks, community cancer centers, academic institutions, and life sciences organizations. The platform facilitates multidisciplinary case discussions, comprehensive tumor conference management, and clinical trial research participation, serving over 100 community cancer centers and oncology practices across the United States.OncoLens generates its revenue primarily through subscription models tailored for healthcare providers and institutions. Clients, including community cancer centers and academic institutions, enter into annual partnership agreements that provide access to OncoLens's complete suite of offerings, including analytics and case management tools. This model aids in ensuring operational efficiency for their users.With the recent Series B funding of USD 12.86 mn, OncoLens plans to enhance its oncology-focused AI capabilities and collaboration solutions. The company aims to expand its presence in new markets across the United States, focusing specifically on optimizing cancer treatment pathways. These initiatives align with OncoLens's commitment to improving cancer care delivery, leveraging its innovative platform.

## Funding rounds

- Series B, Oct 2, 2024, $13M — BIP Ventures, Martin Ventures, SeedtoB Capital, Cross-Border Impact Ventures
- Series A, Jan 13, 2021, $7.3M — BIP Ventures, Martin Ventures, SeedtoB Capital
- Seed, Jan 6, 2020, $2.5M — Atlanta Technology Angels, BIP Ventures, Robbins Fund Inc
- Seed, Mar 26, 2019, $1.4M — Atlanta Technology Angels, BIP Ventures
- Seed, Feb 13, 2019, $0.8M — Atlanta Technology Angels, BIP Ventures

## Investors

- Atlanta Technology Angels (https://capitalatlas.ai/funds/atlanta-technology-angels) — Seed
- BIP Ventures (https://capitalatlas.ai/funds/bip-ventures) — Seed, Series A, Series B
- Robbins Fund Inc — Seed
- Martin Ventures (https://capitalatlas.ai/funds/martin-ventures) — Series A, Series B
- SeedtoB Capital (https://capitalatlas.ai/funds/seedtob-capital) — Series A, Series B
- Cross-Border Impact Ventures (https://capitalatlas.ai/funds/cross-border-impact-ventures) — Series B